February 23, 2023 10:31 AM EST
R&D
Cell/Gene Tx

Sick­le cell R&D hit by three culls in one day at No­var­tis/In­tel­lia, Sang­amo and Graphite Bio

Kyle LaHucik

Senior Reporter

Three biotechs dis­closed pull­backs on sick­le cell dis­ease R&D in the span of 16 hours: with Graphite Bio end­ing work, Sang­amo Ther­a­peu­tics search­ing for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times